VistaGen Therapeutics

-$0.11 (-4.40%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell VTGN and other ETFs, options, and stocks.

About VTGN

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder (SAD); PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD); and AV-101 which the company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.

CEO
Shawn K. Singh
Employees
21
Headquarters
South San Francisco, California
Founded
1998

VTGN Key Statistics

Market Cap
461.04M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
934.07K
High Today
$2.56
Low Today
$2.38
Open Price
$2.56
Volume
1.28M
52 Week High
$3.55
52 Week Low
$0.6088

VTGN Earnings

-$0.30
-$0.20
-$0.10
$0.00
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Nov 11, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure